Clinical Trial 23625

• Overview

  Study Title:

  A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

  Summary:

  Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutecan alone. In arm 2 Participants will receive SOC alone. The study will run for a duration of approximately 51 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

  Objective:

  Primary Objective: * To evaluate the efficacy of telisotuzumab adizutecan monotherapy as measured by DFS by investigator. Secondary Objectives: * To evaluate clinical outcomes of telisotuzumab adizutecan monotherapy as measured by ctDNA clearance rate at 6 months. * To evaluate clinical outcomes of telisotuzumab adizutecan monotherapy as measured by OS. * To evaluate the safety and tolerability of telisotuzumab adizutecan monotherapy. * To evaluate the PK and immunogenicity of telisotuzumab adizutecan monotherapy.

• Treatments

  Therapies:

  c-Met targeting antibody conjugated to a potent inhibitor

  Medications:

  Telisotuzumab Adizutecan ()

• Inclusion Criteria

  Key Inclusion Criteria:
  • Has histologically or cytologically confirmed adenocarcinoma of the colon or rectum.
  • Surgical tumor material should be available and must be submitted for Signatera personalized panel and assessment of c-Met protein levels.
  • Must have received at least 3 months of platinum-based doublet adjuvant chemotherapy but may not have been treated with topoisomerase inhibitors as part of adjuvant therapy.
  • Has no radiographic evidence of disease (NED) confirmed by chest, abdominal, and pelvic computed tomography (CT) scans within 6 weeks prior to Cycle 1 Day 1 (C1D1) dosing.
  • Circulating tumor deoxyribonucleic acid (ctDNA) positive after the end of adjuvant therapy and begin the treatment within 6 weeks after ctDNA is confirmed (reported).
  • For participants with rectal cancer a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet must have been administered. Please note that short course radiation or long-course chemoradiation does not count towards this 3-month minimum of platinum-doublet perioperative and/or adjuvant therapy.
  • For participants with oligometastatic disease a total of at least 3 months of perioperative and/or adjuvant platinum-based doublet therapy must have been administered.

• Exclusion Criteria

  Key Exclusion Criteria:
  • No availability of surgical tissue sample.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.